Abstract High-dose melphalan at 200 mg/m2 (MEL-200) is the standard conditioning regimen before autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). Busulfan (BU) and cyclophosphamide (CY) can be used as alternatives when MEL is unavailable. However. most studies on BU/CY conditioning regimens were conducted before proteasome inhibitors (PIs) and immunom... https://www.lolasalinas.com/